INVARIANT LLC for CIGNA CORPORATION
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues related to H.R. 748/S. 684, Middle Class Health Benefits Tax Repeal Act of 2019, legislation to repeal a 40% ACA excise tax on certain employer-sponsored health insurance plans; issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act; issues related to S.172/H.R. 1398, the Health Insurance Tax (HIT) Relief Act of 2019, legislation to suspend the ACA's health insurance tax (HIT) in 2020 and 2021. S.80, Jobs and Premium Protection Act, full repeal of the HIT.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
| KATHRYN WISE | — |
Health Issues HCR
Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; and H.R. 3630, The No Surprises Act, and H.R. 5800, The Ban Surprise Billing Act; issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act. P.L. 116-136., Coronavirus Aid, Response, and Economic Security Act (CARES Act). HR 6379, Take Responsibility for Workers and Families Act; issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
| KATHRYN WISE | — |
Medicare/Medicaid MMM
Monitor issues related to Medicare Advantage Program; Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act; proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices; S. 2543, The Prescription Drug Pricing Reduction Act of 2019.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
| KATHRYN WISE | — |
Pharmacy PHA
Pharmacy issues related to S. 1895, the Lower Health Care Costs Act; issues related to drug shortages, and pharmaceutical procurement processes; issues related to H.R. 3, the Lower Drug Costs Now Act of 2019.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
| KATHRYN WISE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.